全球九大CGT组织代表首次齐聚中国，2026 CSGCT年会启动全球细胞与基因治疗合作新篇章
Unprecedented! Nine leading global CGT organizations gather in China for the first time, marking the launch of 2026 CSGCT and a new chapter in global collaboration on cell and gene therapy.
2026年9月19-20日，2026 CSGCT年会将在北京中关村国家自主创新示范区展示交易中心举行，ISCT、ASGCT、ACTO等全球九大细胞与基因治疗组织核心代表将首次同时在中国亮相。会议将围绕全球监管趋势、前沿技术突破、临床转化路径及国际合作展开讨论，ASGCT主席Barry J. Byrne、JSGCT主席Yoshikazu Yonemitsu等将出席分享。
If there were a conference that brought together the United States, Japan, South Korea, India, Brazil, Australia, and…For the first time, core representatives from ISCT, ACTO and other of the world’s top nine cell and gene therapy （CGT） organizations have gathered in China to engage in face–to–face discussions with domestic research institutions, clinical experts, and innovative companies—would you like to attend？
On 19–20 September 2026, at the Beijing Zhongguancun National Independent Innovation Zone Exhibition and Trade Center, this historic scene will become a reality. The 2026 CSGCT Annual Meeting will see the first simultaneous appearance of core representatives from nine major global CGT organizations, who will engage in in–depth discussions on global regulatory trends, cutting–edge technological breakthroughs, clinical translation pathways, and international cooperation within the industry.
This is not merely an industry event featuring an upgraded international lineup—it also signifies that China’s CGT sector is becoming increasingly integrated into the global innovation network。Following international conferences such as ESGCT and ASGCT, 2026 CSGCT will become an important “Chinese station” in the global CGT exchange landscape, linking innovative forces around the world to jointly explore the next phase of the cell and gene therapy industry.
01
When CGT enters a new stage of global competition
China needs a platform to connect with the world.
In recent years, cell and gene therapy has emerged as one of the most promising areas of development within the field of life sciences worldwide. From the commercialization of CAR–T therapy to ongoing breakthroughs in gene editing technology；From research into gene therapy for rare diseases to the rapid development of next–generation cell therapy platforms, CGT is helping to push the life sciences and health industry into a new period of innovation.
But at the same time, the industry faces new challenges:
How to navigate global regulatory trends?
How can innovative therapies move from the laboratory to the clinic?
How to achieve the large-scale production and commercial application of technological achievements?
How to find international cooperation opportunities in the global competitive landscape?
These issues have become the core issues of common concern to the global CGT industry.
The industry needs a platform that connects research, clinical, corporate, investment and international organizations, so that the experience, resources and innovation forces of different countries and regions can truly be exchanged and integrated. CSGCT 2026 is held in this context.
02
The world's nine major CGT organizations gathered for the first time
China welcomes international CGT forces。"Large collection "
The CSGCT invited representatives from a number of core CGT organizations around the world, including:
ASGCT, American Society of Gene & Cell Therapy;
ISCT, International Society of Cell and Gene Therapy;
ACTO, Asian Cell Therapy Organization;
Brazilian Association of Cells and Genes;
AGCTS, Australian Society of Gene Cell Therapy;
India Society of Cell and Gene Therapy;
JSGCT, Japan Society of Gene and Cell Therapy;
KSGCT, Korean Society of Gene and Cell Therapy;
These organizations represent the core forces driving CGT development across different global regions: the United States embodies the innovation systems and industrial expertise of mature markets. Japan and South Korea serve as practical models for the advancement of cutting-edge medical therapies in Asia. India and Brazil represent the potential for rapid development of emerging CGT markets; Australia represents innovation in gene therapy basic research and clinical translation.
From mature markets to emerging markets, from scientific research innovation to industrial transformation, the important voices on the global CGT map will be presented in CSGCT for the first time.
03.
The global CGT leader line-up debut,
What will they share at CSGCT?
The arrival of representatives of nine major international organizations is not just an upgrade of the guest lineup.
What they bring is the development experience and strategic insights of the global CGT industry over the next decade.
Barry J. Byrne
Chairman of the American Society of Gene & Cell Therapy (ASGCT)
As one of the largest gene and cell therapy professional organizations in the world, ASGCT has long promoted scientific research, clinical translation and global collaboration in the field of gene therapy.
Professor Barry J. Byrne has a long history of research in Keene therapy and rare diseases and is a key international expert in the field of Keene therapy.
As President of ASGCT, he not only represents the cutting-edge direction of the U.S. cell and gene therapy industry but will also contribute key insights on global regulatory trends, the translation of innovative technologies, and industry collaboration.
His arrival signifies that a key voice from one of the world's most mature CGT markets will directly contribute to the development of China's CGT ecosystem.
01
Yoshikazu Yonemitsu
President of the Japanese Society for Gene and Cell Therapy (JSGCT)
Professor Yoshikazu Yonemitsu is a key figure in advancing gene and cell therapy in Japan.
He received his Doctor of Medicine from Kyushu University and worked as a Wellcome Trust researcher at Imperial College of Science and Technology in London to conduct research on Gene therapy.
Over the past two decades, Professor Yonemitsu has continued to promote the translation of basic research to clinical applications, and has extensive experience in the fields of gene therapy, cell therapy, cancer free therapy and regenerative medicine.
As the president of JSGCT, he has actively promoted the development of Japan's CGT industry and international exchanges.
The company’s leading developed allogeneic NK–like cell therapy product, GAIA–102, is currently undergoing clinical research for conditions such as pediatric solid tumors and peritoneal metastases from gastric cancer and pancreatic cancer.
During his visit to CSGCT, he will share Japan's experiences in the industrialization of advanced therapies, clinical translation, and international collaboration.
02
Miguel Forte
Past President, ISCT, International Society for Cell and Gene Therapy
Co-Founder and CEO, Kiji Therapeutics
Miguel Forte is a leading figure in the global cell and gene therapy industry.
He has served as President of the ISCT and currently serves on the ISCT Board of Directors, as well as Chair of the European Advisory Committee of the Alliance for Regenerative Medicine (ARM).
As a cell and gene therapy developer, he founded and led several innovative companies and has extensive experience in commercializing CGT, regulatory systems and industrial strategy.
In addition, he has regulatory work with the European Medicines Agency (EMA) and has global management experience in large pharmaceutical companies.
Miguel Forte, who has a doctor of medicine and a doctor of non-epidemic medicine, has a profound accumulation in the three dimensions of scientific research, supervision and industry.
His participation will provide important reference for Chinese enterprises exploring global markets and promoting international cooperation.
03
Martin Bonamino
President of the Brazilian Association for Cell and Gene Therapy (ABTCel-Gen)
Head of the Cell and Gene Therapy Program at the National Cancer Institute in Brazil
Dr. Martin Bonamino is an important representative in the field of CGT in Brazil.
He holds a degree in Biomedical Sciences from the Federal University of Rio de Janeiro and a PhD in Medical Chemistry, and has conducted research at institutions such as the Mario Negri Institute in Italy.
Currently, he is responsible for the Cell and Gene Therapy Program at the National Cancer Institute in Brazil and is president of the Brazilian Society for Cell and Gene Therapies.
Previously, he served as Chair of the ASGCT Global Cooperation Committee and was responsible for the ISCT South and Central America Regional Regulatory Affairs.
He has long promoted the development of CAR-T and advanced therapeutic technologies in Brazil.
At the CSGCT, he will share the current state of the development of advanced therapies in Brazil and the important exploration of the National Cancer Institute in the field of CAR-T.
04
Samantha Ginn
AGCTS President, Australian and Oceania Gene and Cell Therapy Society
Associate Professor Samantha Ginn is a leading scientist in the field of Keine therapy in Australia.
She has held a long–term position at the Institute of Pediatric Medicine （ CMRI ）。I am part of a gene therapy research team and also hold a research position at the School of Medicine and Health, University of Sydney.
Over the past 20 years, she has focused on gene delivery systems, AAV vectors, lipid nanoparticles, and gene editing technologies.
Her research focuses on the treatment of genetic disorders in children, including metabolic liver disease, congenital adrenal hyperplasia and neurofibromatosis.
As President of the Australian Society for Gene Cell Therapy, she will share CGT research innovation, clinical transformation and industry trends in Australia and New Zealand at CSGCT.
05
Arkasubhra Ghosh
Representative of the Indian Society for Cell and Gene Therapy
Dr. Arkasubhra Ghosh is a key driver in the field of cell and gene therapy in India.
As one of the world's fast-growing CGT emerging markets, India has made breakthroughs in the research and development of CAR-T, Keine therapy and clinical application in recent years.
Dr. Ghosh will represent India's CGT ecosystem, engaging with Chinese counterparts to discuss market development, innovative models, and future collaboration opportunities in India.
06
Akihiro Shimosaka
President of the Asian Cell Therapy Organization ACTO
Dr. Akihiro Shimosaka is a key leader of the Asian Cell Therapy Organization (ACTO).
ACTO is jointly promoted by multiple Asian countries and regions, including Japan, China, South Korea, India, and Singapore, with the aim of fostering exchange and collaboration in the field of cell therapy across Asia.
As Chairman of ACTO, he will promote synergy among the CGT industry in Asia and strengthen interregional scientific, clinical and industrial cooperation.
His participation also reflects the Asian CGT ecology is forming a closer cooperation network.
07
04
They brought more than just reports.
But the future direction of global CGT
Representatives from nine major international organizations gathered at CSGCT—and this event was far more than just an international exchange。What they brought was : global regulatory trends。Paths of CGT industrial development in different countries; Experience in clinical translation of innovative technologies; Overseas market entry strategy;Opportunities for international cooperation.
The CSGCT conference will focus on a number of topics of global concern, including:
Building strength through mutual collaboration – A forum on the collaborative evolution and multilateral cooperation of the global CGT network United in Synergy: The Global CGT Forum for Co–Evolution Multilateral Cooperation
From cross-border collaboration to global sharing: building clinical and innovation communities that benefit patients
The evolving field of C>. New business models, geography and the 3-Body Problem
China IIT Empowering innovation across the globe
The landscape of advanced therapies in Brazil and ongoing initiatives at the National Cancer Institute
Building bridges: Berlin's CGT Ecosystem as a Gateway to European Markets
05
23 Professional Forums
A key window into the next decade of global CGT
There are many conferences in the field of CGT in China, but national conferences that truly bring together global industry organizations, cover the entire industrial chain, and connect innovative resources and business opportunities are still scarce.
The 2026 CSGCT China Cell and Gene Therapy Conference is not merely an academic exchange event; it serves as a crucial platform for connecting China's CGT industry with global innovation forces.
This year’s conference will focus on key areas such as basic research, technological innovation, clinical translation, industrial manufacturing, regulatory science, business collaboration, and global expansion to create a high–level exchange platform that spans the entire CGT life cycle.
Over two days, 23 professional forums brought together top experts, business leaders, representatives of scientific research institutions, clinical experts and heads of investment institutions from many countries and regions around the world to discuss the future direction of cell and gene therapy in the next decade.
Here you can:
Stay up to date with the latest technologies and industry trends. The conference covers, but is not limited to, CAR–T and next–generation cell therapy technologies。These topics—including innovative gene therapy technologies and delivery systems, AI–enabled CGR research and clinical translation, cell therapy commercialization and CMC challenges, IIT research and clinical innovation models, global regulatory trends in CGT, corporate internationalization, and market expansion into overseas regions—will help attendees quickly grasp the industry’s future directions.
Connect industry partnership resources. CSGCT does not merely focus on scientific breakthroughs—it also pays close attention to how innovative results can truly reach the clinic and the market。The conference will bring together CGT innovators from home and abroad, leading research institutions, top–tier hospitals and clinical experts, investment firms, and industrial capital to create more opportunities for technical cooperation, project exchanges, industrial investment, and international collaboration.
Face-to-face communication with leading global CGT experts. Core representatives from the United States, Japan, South Korea, India, Australia, Brazil, and international organizations will share the latest global trends in cell and gene therapy (CGT), regulatory changes, and industry development experiences.
This is a space where resources come together. Whether you are looking for technological breakthroughs, clinical collaborations, regulatory guidance, or international BD and financing opportunities, the CSGCT Annual Meeting will be an essential strategic opportunity not to be missed in 2026.
From September 19-20, 2026, the CSGCT Annual Meeting will be held at the Zhongguancun Convention Center in Beijing. As an international exchange platform for the global field of cell and gene therapy, this conference will bring together 300 + global regulatory, clinical and industry experts and 3000 + attendees.
Free tickets for CSGCT, scan the QR code to get them now
For business cooperation and consultation, please contact:
Ms. Lee, CSGCT Secret Service
Email: join@csgct.com.cn
Phone / WeChat: 18600921680
2026
CSGCT Annual Meeting Related Reports
Top guests
General Assembly Information
International exchanges
Across Mountains and Seas, Discuss the Future | CSGCT Joint Pavilion at the 2026 ASGCT Annual Meeting
Debut at ASGCT | CSGCT Brings "China's CGT Voice" to Boston
About CSGCT
The Purpose and Orientation of CSGCT Alliance and Congress
Promoting the application of CGT technology in China aims to alleviate patient suffering and save lives through effective treatment.
To become a platform for scientists, physicians, patient organizations, regulatory agencies, enterprises, and investors in China's cell and gene therapy (CGT) sector to gather and collaborate.
Promote the brand value of China's CGT industry, accelerate deep global integration, and advance access to innovative therapies.
Vision of the CSGCT Coalition and Congress
Promoting Innovation and Translation: Focusing on the cell and gene therapy (CGT) sector, we bridge the entire chain from basic research and technology development to clinical trials and industrial commercialization, accelerating the integration of China's CGT products, technologies, and services into the global market.
Build synergy ecology: By integrating domestic and foreign research resources, clinical institutions, enterprises and capital, we can build a multidimensional synergy platform of "politics, production, schools, research, medical - financial" to promote solutions to common industry challenges (such as financing needs, regulatory communication, supply chain stability, international cooperation, etc.).
来源：动脉网 · vbdata.cn